2Murcia J M, Gonzalez-Corneche J, Marin A, et al. Clinical re?sponse to ertapenem in severe community-acquired pneumoni?a: a retrospective series in an elderly population[J]. Clin Mi?crohiol Infect, 2009,15(11): 1046-1050.
5Navarro NS Jr, Campos MI, Alvarado R, et al. ertapenem versus ceftriaxone and metronidazole as treatment for complicated intraabdminal infections [ J ]. Inter J Surg,2005,3:25 - 34.
6Namias N, Solomkin JS, Jensen EH, et al. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenems verus piperacillin/tazobactam in treatment of complicated intra-abdominal infections [ J ]. Surg Infect ( Larchmr) ,2007,8(1) : 15 -28.
7Carmeli Y,Lidji S,Shabtai E,et al. the effects of group 1 vs group 2 carbapenems on imipenem resistant (IMP-R) P. aeruginosa (PA) : ecological study, poster on 48th ICAAC 2007 Chicago [ C ] , Illinois.
8Goff DA, Mangino JE. Ertapenem:no effect on aerobic gram-negative susceptibilities to imipenem [ J ]. J Infect, 2008,57 : 123 - 127.
9Crank C, Hota B, Segreti J. Effect of ertapenem utilization on pseudomonas aeruginosa susceptibility to imipenem. Poster on 44th Infectious Disease Society of America 2006 Toronto[ C] ,Canada.
10Goldstein EJC, Citron DM, Peraino V, et al. Introduction of ertapenem onto a hospital formulary:effect on antimicrobial usage and the in vitro susceptibility on aerobic gram-negative rods[ R]. Poster on 44th Infectious Disease Society of America, 2006 Toronto, Canada.
